BLACANDI can improve life quality and cut cost of diagnosing and managing bladder cancer in half

Informacje na temat projektu

BLACANDI

Identyfikator umowy o grant: 673077

DOI

10.3030/673077

Projekt został zamknięty

Data podpisania przez KE 10 Czerwca 2015

Data rozpoczęcia 1 Lipca 2015

Data zakończenia 31 Grudnia 2015

Finansowanie w ramach

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Koszt całkowity

€ 71 429,00

Wkład UE

€ 50 000,00

Koordynowany przez

GENOMIC EXPRESSION APS
Denmark

Periodic Reporting for period 1 - BLACANDI (BLACANDI can improve life quality and cut cost of diagnosing and managing bladder cancer in half)

Okres sprawozdawczy: 2015-07-01 do 2015-12-31

Podsumowanie kontekstu i ogólnych celów projektu

BLACANDI is based on a successfully concluded small fully randomized blinded clinical study of 500 patients presenting with blood in the urine meeting its end-point of a sensitivity of +90%.

The Horizon2020 phase I feasibility study identified no competitors that could match this end-point; however, a number of competing approaches was identified, which will supplement cytology rather than substitute cystoscopy - and as a result increase cost of care.

Implementation into standard of care would require a clinical study of 4000 patients representing with blood in the urine’ which is planned as the phase II of the BLACANDI Horizon2020 project.

The overall objective of the Bladder Cancer Diagnostic “BLACANDI” project (Phase I + II) is to eliminate or dramatically reduce the use of cystoscopy in the diagnosis and follow-up of bladder cancer patients, and thereby reduce the cost of care of bladder cancer.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

The clinical study performed meet the end-point of +90% sensitivity. All task associated with moving the BLACANDI solution to market through regulatory, IP, engagement with Key Opinion Leaders, clinical trail planning and commercialization plan was executed.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

Many academic institutions and commercial companies has identified many different markers for bladder cancers, however so far all single or combination of markers have failed to match the performance of cystoscopy and for that reason implementation of those markers will only increase cost of care.

Bladder cancer is one of the most expensive cancers to manage. Only 1 out of 10 patients presenting with blood in the urine has bladder cancer; however, in the absence of better assays capable of identifying more than 90% of all cancer cases, cystoscopy has remained the standard of care.

In Europe €1.8 billion/year is spend on cytoscopy just for diagnosing the disease. Due to the risk of recurrence all patients undergo routine cystoscopy often several times/year. Managing recurrence is estimated to cost an additional €1.8 billion/year.
Implementing the BLACANDI system instead of cystoscopy could cut the cost of diagnosing and managing bladder cancer in half.

figure.jpg